ClinicalTrials.gov
public full text
Public Domain
TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients
A Phase II study evaluating the safety and efficacy of TGRX-678 in Chronic Myelogenous Leukemia (CML) patients in Accelerated phase (AP) and are relapsed or refractory from third-generation Tyrosine Kinase Inhibitor (TKI) treatment
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population#886237
- TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients#885640
- A Study for Tyrosine Kinase Inhibitors Discontinuation#896028
- CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL#812251
- Follow-up Study on Chronic Myeloid Leukemia Patients Achieving Treatment-free Remission#908661
Record · ID 1007074
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive